ACRX - AcelRx Pharmaceuticals, Inc.
| Previous Close | 1.6700 |
| Open | 1.6600 |
| Bid | 1.6100 x 4000 |
| Ask | 1.6500 x 4000 |
| Day's Range | 1.6000 - 1.6700 |
| 52 Week Range | 1.6000 - 4.0900 |
| Volume | 1,029,132 |
| Avg. Volume | 865,663 |
| Market Cap | 127.317M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6690 |
| Earnings Date | Nov 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.80 |
- Simply Wall St.
Should You Worry About AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Salary Level?
Vince Angotti has been the CEO of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) since 2017. This report will, first...
- Zacks
AcelRx Pharmaceuticals (ACRX) Stock Moves -1.14%: What You Should Know
In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.73, marking a -1.14% move from the previous day.
- Zacks
AcelRx Pharmaceuticals (ACRX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.91, marking a -0.78% move from the previous day.
- PR Newswire
AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today provided an update on its business and DSUVIA® launch metrics.
- Zacks
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study
Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.
- Zacks
Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA
The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).
- Zacks
Catalyst Gives Preliminary Firdapse Estimates & Other Updates
Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.
- Zacks
Have Faith in Rising P/E: Play 5 Top-Ranked Stocks
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
- Zacks
AcelRx Pharmaceuticals (ACRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Top Ranked Momentum Stocks to Buy for January 3rd
Top Ranked Momentum Stocks to Buy for January 3rd
- Zacks
Jazz Enrolls First Patient in Phase II/III Leukemia Study
Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases
- Simply Wall St.
How Much Are AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Insiders Spending On Buying Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- Insider Monkey
Is AcelRx Pharmaceuticals Inc (ACRX) A Good Stock To Buy?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Is AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) a […]
- Zacks
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M
Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.
- Zacks
AcelRx Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
AcelRx Pharmaceuticals, Inc. (ACRX) has been struggling lately, but the selling pressure may be coming to an end soon.
- PR Newswire
AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets
REDWOOD CITY, Calif. , Nov. 13, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- Zacks
AcelRx Pharmaceuticals Enters Oversold Territory
AcelRx Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Thomson Reuters StreetEvents
Edited Transcript of ACRX earnings conference call or presentation 6-Nov-19 10:00pm GMT
Q3 2019 AcelRx Pharmaceuticals Inc Earnings Call
- Simply Wall St.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX): Is Breakeven Near?
AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX): AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses...
- Zacks
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 30.43% and -50.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results
Exceeded 125 REMS-certified facilities two months ahead of year-end goal 105 formulary approvals through October 31 $80.4 million of cash and short-term investments at September 30, 2019 REDWOOD CITY, ...
- PR Newswire
AcelRx Pharmaceuticals to Present at Credit Suisse 28th Annual Healthcare Conference
REDWOOD CITY, Calif. , Nov. 5, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- Zacks
Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q3 Earnings Expected to Decline
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
AcelRx to announce third quarter 2019 results and provide an update on the company's business on Wednesday, November 6th, 2019
REDWOOD CITY, Calif. , Oct. 28, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results ...
- Zacks
AcelRx Pharmaceuticals (ACRX) Moves to Buy: Rationale Behind the Upgrade
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
